CORE EARNINGS PER SHARE: Core earnings per share are expected to rise to $2.07 from $1.45 the year prior, according to the same consensus. AstraZeneca's stock is up 7.9% since the start of 2024.

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

In a report released today, James Gordon from J.P. Morgan maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target ...

For the first half of the fiscal year, analysts anticipate organic sales growth of 0.5%, net sales of $10.7bn and a 2% ...

A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...

Great Diamond Partners LLC decreased its position in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.2% during the ...

Mediolanum International Funds Ltd decreased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 67.7% ...

Indian stock markets closed the special trading session on account of the Union Budget 2025-26 on a flat note. The Nifty 50 closed the session 13.45 points, or 0.06%, lower at 23,494.95. The Sensex ...

Hapless Chancellor Rachel Reeves has hit on an unusual way of generating growth. By waging war on UK businesses.

Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications ...

In a report released yesterday, Seamus Fernandez from Guggenheim reiterated a Buy rating on AstraZeneca (AZN – Research Report), with a price ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...